Riccardo De Giorgi

Petition to make Matt Berry the next James Bond.

🧠📱 Check out our new open-access paper: “A Survey of Preferences for Sensing Technologies in People with Severe Mental Illness in Acute Psychiatric Care” published in #AnnalsofBiomedicalEngineering Read it at link.springer.com/article/10.100…

Delighted to feature in "The unexpected ways Ozempic-like drugs might fight dementia" nationalgeographic.com/health/article… via @NatGeo

#GLP1RAs were associated with improved #QualityOfLife metrics and #EmotionalEating behaviors among individuals with #overweight and #obesity. @KingsIoPPN @GSTTnhs @ImperialMed @UniofOxford @OxfordHealthNHS @rdegiorgi @tobypill endocrinologyadvisor.com/news/glp-1ras-…

Simvastatin added to escitalopram did not improve depressive symptoms in patients with major depressive disorder and obesity, although it reduced cholesterol and C-reactive protein levels. ja.ma/43Hi33P

Most viewed this week from @JAMAPsych: GLP1-RA treatment for obesity and diabetes does not increase psychiatric adverse events compared to placebo and is linked to improvements in quality of life, emotional eating, and mental well-being. ja.ma/44Voqmu

Most viewed this week from @JAMAPsych: GLP1-RA treatment for obesity and diabetes does not increase psychiatric adverse events compared to placebo and is linked to improvements in quality of life, emotional eating, and mental well-being. ja.ma/43owISN

Most viewed this week from @JAMAPsych: GLP1-RA treatment for obesity and diabetes does not increase psychiatric adverse events compared to placebo and is linked to improvements in quality of life, emotional eating, and mental well-being. ja.ma/4kqyZ5r

🔙 #tbt #MentalHealthAwarenessMonth 🚨@rdegiorgi et al. from the @UniofOxford present a thorough analysis of pre-clinical and clinical studies examining the role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in #mental disorders. nature.com/articles/s4422…